Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-interleukin-13 receptor alpha 2 allogeneic CAR T cells YYB-103

A preparation of T lymphocytes genetically modified to express a chimeric antigen receptors (CAR) specific for interleukin-13 receptor alpha 2 (IL13Ra2), with potential immunostimulating and antineoplastic activities. Upon administration, the anti-IL13Ra2 CAR T cells YYB-103 target and bind to IL13Ra2 expressed on the surface of tumor cells. This induces selective toxicity in tumor cells expressing IL13Ra2. IL13Ra2, a cancer-associated receptor, is overexpressed by a variety of tumor cell types including glioblastoma multiforme (GBM); it is associated with increased invasiveness of tumor cells.
Synonym:anti-IL13Ra2 CAR T cells YYB-103
anti-IL13Ra2 CAR-T cells YYB-103
IL13Ra2-targeted CAR-T cells YYB-103
Code name:anti-IL13Ralpha2 CAR T cells YYB-103
YYB 103
YYB-103
YYB103
Search NCI's Drug Dictionary